Myeloma Chronic Articles & Analysis
3 news found
The delivery system and program have proven viability and we believe we are well situated to advance to Phase 1b/2 in multiple myeloma patients.” The Company previously announced that the upcoming Phase 1b/2 clinical study in multiple myeloma is on track to begin enrollment in Q4 2022 at three already identified sites in the European Union. ...
Sebia, a world leader in diagnostics in the fields of multiple myeloma and chronic diseases, and Metafora biosystems ("Metafora") today announced a strategic partnership to develop a portfolio of in-vitro diagnostics (IVD) solutions based on Metafora's technology platform. ...
LAVA’s first-in-class gamma-delta bsTCE to be evaluated as a treatment for chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia UTRECHT, The Netherlands and PHILADELPHIA, July 13, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on developing bispecific gamma-delta T cell engagers (bsTCEs) ...